WEE1-targeted treatment for uterine serous and p53-mutant uterine cancer
Targeting WEE1 in uterine serous or p53-mutated uterine cancer
Testing a drug that blocks the WEE1 protein to try to shrink uterine serous cancers and other uterine cancers with p53 mutations.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11323894 on NIH RePORTER |
What this research studies
If you join, researchers will give or study drugs that block the WEE1 protein pathway in people with uterine serous cancer or uterine cancers that have p53 mutations. They will combine laboratory work on tumor samples and models with clinical data from patients to see how tumors respond. The team will look for molecular markers (like TP53, CCNE1, KRAS, MYC changes) that might predict who benefits. Earlier work at this center showed clinical activity for a WEE1 drug, and this project aims to better match patients to effective treatments and test ways to overcome resistance.
Who could benefit from this research
Good fit: Ideal candidates are people with uterine serous carcinoma or uterine cancers confirmed to have TP53 (p53) mutations, especially those with recurrent or advanced disease who may have had prior treatments.
Not a fit: People with other uterine cancer subtypes without p53 mutations, early-stage disease not requiring systemic therapy, or those medically unable to undergo treatment may not benefit from this approach.
Why it matters
Potential benefit: Could provide a new targeted treatment option that shrinks tumors and improves outcomes for people with aggressive uterine serous or p53-mutant uterine cancers.
How similar studies have performed: A prior clinical trial of the WEE1 inhibitor adavosertib at this institution showed meaningful activity (about a 29% response rate), but clear molecular predictors of response remain unconfirmed.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Liu, Joyce — Dana-Farber Cancer Inst
- Study coordinator: Liu, Joyce
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.